Evidence map›Paper›PMID 41626172›Full record

ArticleFrontiers in oncology2025

Case Report: FIA plus venetoclax in a patient on hemodialysis.

Jacob E Herstein, Kayleigh R Marx, J Michael Savoy, Wei Ying Jen, Musa Yilmaz, Nicholas J Short, Ghayas C Issa, Farhad Ravandi, Tapan M Kadia, Naval G Daver and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jacob E HersteinDepartment of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, United States.
Kayleigh R MarxDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
J Michael SavoyDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Wei Ying JenDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Musa YilmazDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nicholas J ShortDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ghayas C IssaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Farhad RavandiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Tapan M KadiaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Naval G DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Courtney D DiNardoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).

Indexed as

acute myeloid leukemiacase reportchemotherapyhematologic oncologyhemodialysis

Identifiers

PMID41626172
PMCPMC12852021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.